The good news keeps rolling for Surrey-based stem cell specialist ReNeuron (RENE). The group has announced plans to extend its research collaboration with Australia-based Benitec Biopharma following positive results in some early studies.
IC TIP:
Sell
at
5.7p
Benitec has discovered ReNeuron's CTX-derived exosomes are an effective delivery system for Benitec's gene 'silencing' technology. This results in the 'switching off' of specific genes in certain cells - to beneficial therapeutic effect. ReNeuron will extend the partnership with Benitec to test this combination technology, specifically targeting lung and other drug resistant cancers.
